Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
- PMID: 2190095
- DOI: 10.1038/345622a0
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
Abstract
The development of a vaccine to provide protective immunity to human immunodeficiency virus type 1 (HIV-1), the virus causing AIDS, would be the most practical method to control its spread. Subunit vaccines consisting of virus envelope glycoproteins, produced by recombinant DNA technology, are effective in preventing viral infections. We have now used this approach in the development of a candidate AIDS vaccine. Chimpanzees were immunized with recombinant forms of the HIV-1 glycoproteins gp120 and gp160 produced in Chinese hamster ovary cells, and then challenged with HIV-1. The control and the two animals immunized with the gp160 variant became infected within 7 weeks of challenge. The two animals immunized with the gp120 variant have shown no signs of infection after more than 6 months. These studies demonstrate that recombinant gp120, formulated in an adjuvant approved for human use, can elicit protective immunity against a homologous strain of HIV-1.
Similar articles
-
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.Dis Markers. 1991 Jan-Feb;9(1):51. Dis Markers. 1991. PMID: 1742945 No abstract available.
-
HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.Vaccine. 1994 Sep;12(12):1141-8. doi: 10.1016/0264-410x(94)90185-6. Vaccine. 1994. PMID: 7998425
-
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.AIDS. 1990 Apr;4(4):307-15. doi: 10.1097/00002030-199004000-00004. AIDS. 1990. PMID: 2190605
-
Human trials of AIDS vaccines: current status and future directions.AIDS. 1989;3 Suppl 1:S125-9. AIDS. 1989. PMID: 2558684 Review. No abstract available.
-
Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.AIDS Res Hum Retroviruses. 1992 Aug;8(8):1349-52. doi: 10.1089/aid.1992.8.1349. AIDS Res Hum Retroviruses. 1992. PMID: 1361352 Review.
Cited by
-
A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: Effects on glycosylation and antigenicity.PLoS One. 2020 Jun 19;15(6):e0231679. doi: 10.1371/journal.pone.0231679. eCollection 2020. PLoS One. 2020. PMID: 32559193 Free PMC article.
-
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2175-9. doi: 10.1073/pnas.89.6.2175. Proc Natl Acad Sci U S A. 1992. PMID: 1549578 Free PMC article.
-
Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.J Virol. 1991 Jul;65(7):3514-20. doi: 10.1128/JVI.65.7.3514-3520.1991. J Virol. 1991. PMID: 2041078 Free PMC article.
-
Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.J Virol. 1992 Mar;66(3):1823-31. doi: 10.1128/JVI.66.3.1823-1831.1992. J Virol. 1992. PMID: 1637373 Free PMC article.
-
A Multi-Vector, Multi-Envelope HIV-1 Vaccine.J Pediatr Pharmacol Ther. 2007 Apr;12(2):68-76. doi: 10.5863/1551-6776-12.2.68. J Pediatr Pharmacol Ther. 2007. PMID: 23055844 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
